AMID Co., Feb 2009, Pages: 173
economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003
Draco Healthcare Consulting LLC, March 2009, Pages: 106
data monitor system that the China Nan Fang Institute has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled
AMID Co., June 2009, Pages: 191
economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003
Espicom Business Intelligence Ltd, June 2007, Pages: 160
Terbinafine
ISSUES AFFECTING THE UK GENERIC MARKET
When is a generic prescription not a generic prescription?
Despite great emphasis being placed on generic prescribing, a significant number of generic
Sunfaith China Ltd, Dec 2006, Pages: 20
, fluconazole, itraconazole and terbinafine were in the first three places.
Among the TOP 20 manufacturers in market share in 2004, 9 are foreign enterprises and joint ventures and 11 are Chinese enterprises
Sunfaith China Ltd, Dec 2006, Pages: 20
, itraconazole and terbinafine were in the first three places.
Among the TOP 20 manufacturers in market share in 2004, 9 are foreign enterprises and joint ventures and 11 are Chinese enterprises. Pfizer
Informa Healthcare, May 1993, Pages: 488
- in vitro and in vivo activities of naftifine, Hubert Mieth, biochemical mode of action of naftifine, Neil S. Ryder, clinical experience with naftifine, Matthias Brautigam and Gottfried Weidinger; terbinafine
John Wiley and Sons Ltd, March 2008, Pages: 272
, the summary of its industrial development, the year put into practice, the biological target for the medicine, the human proteins related to the disease, the metabolism or action of the condition treated
Manson Publishing, Jan 2002, Pages: 256
There has been an increase in the use of systemic drug therapy for skin diseases during recent years. This reflects advances in drug development but many are potent drugs which can have serious
